ClinicalTrials.gg
CompletedNCT01483144Updated Jun 8, 2021Results posted

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

A Phase 3 interventional study of Eflornithine and Eflornithine Placebo in Familial Adenomatous Polyposis, sponsored by Cancer Prevention Pharmaceuticals, Inc.. Completed at 17 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Cancer Prevention Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.

Enrollment
4th of 27
171 · median 42
Started
2013
with 1 other
Phase 3
3 of 39
1 open now
Registered
14th of 39
by date
Lead sponsor
1 of 39
Cancer Prevention Pharmaceuticals, Inc.

Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 4th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 14th registered.

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

Browse Adenomatous Polyposis Coli studies →

Open to participants now

12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Adenomatous Polyposis Coli with a site in United States, or all of them as a file.
02

Study summary

The purpose of this randomized, double-blind, Phase III trial is to determine if the combination of eflornithine plus sulindac is superior to sulindac or eflornithine as single agents in delaying time to the first occurrence of any FAP-related event. This includes: 1) FAP related disease progression indicating the need for excisional intervention involving the colon, rectum, pouch, duodenum and/or 2) clinically important events which includes progression to more advanced duodenal polyposis, cancer or death.

03

Conditions studied

  • Familial Adenomatous Polyposis

Keywords

  • Familial Adenomatous Polyposis
  • Eflornithine
  • Sulindac
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or colon/rectum/pouch.

    1. Genotype: Adenomatous polyposis coli (APC) mutation (with or without family history) required
    2. Classical FAP Phenotype: 100's to 1,000's of colorectal adenomatous polyps, usually appearing in teenage years
  • Upper gastrointestinal (UGI) endoscopy/ lower gastrointestinal (LGI) endoscopy (proctoscopy/colonoscopy) performed within 30 days of randomization.
  • Patients with an intact colon/rectum, except for clinical polyposis, and prophylactic surgery is being considered as a stratification site.
  • Rectal/pouch polyposis as a stratification site as follows:

    1. At least three years since colectomy with ileorectal anastamosis (IRA)/proctocolectomy with pouch, and demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 Staging System (Appendix B) and summarized as follows:

      Stage 1: 10-25 polyps, all \< 5 mm Stage 2: 10-25 polyps, at least one > 1 cm Stage 3: >25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high grade dysplasia, even if completely removed. [Note: For staging purposes only.]

    2. For all subjects, any rectal/pouch polyps > 5 mm must be excised at "baseline".
  • Duodenal polyposis as a stratification site; one or more of the following:

    1. Current Spigelman Stage 3 or 4.
    2. Prior surgical endoscopic intervention within the past six months for Spigelman Stage 3 or 4 that may have been down staged to Spigelman Stage 1 or 2.
  • Hematopoietic Status (within 30 days prior to randomization):

    1. No significant hematologic abnormalities
    2. White blood cell count (WBC) at least 3,000/mm3
    3. count at least 100,000/mm3
    4. at least 10.0 g/dL
    5. No history of clinical coagulopathy
  • Hepatic Status (within 30 days prior to randomization):

    1. no greater than 1.5 times
    2. (AST) and alanine aminotransferase (ALT) no greater than 1.5 times ULN
    3. Alkaline phosphatase no greater than 1.5 times ULN
  • Renal Status (within 30 days prior to randomization):

    a) Creatinine no greater than 1.5 times ULN

  • Hearing:

    a) No hearing loss, defined in Section 6.2, number 9.

  • If female, neither pregnant nor lactating.
  • Negative pregnancy test if female of . Fertile patients must use effective *.
  • Absence of gross blood in stool; red blood on toilet paper only acceptable.
  • No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated with antibiotics.
  • No invasive within the past 5 years except resected non-melanomatous skin cancer, papillary thyroid cancer, or precancerous cervical dysplasia.
  • No other significant medical or psychiatric problems that would preclude study participation or interfere with capacity to give .
  • Use of 81-100 mg daily aspirin or up to 700 mg aspirin not more than once a week are eligible.
  • No concurrent warfarin, fluconazole, lithium, Pradaxa® or other direct thrombin inhibitors, Plavix®, cyclosporine, other NSAIDs (such as ibuprofen, aspirin, diflunisal), diuretics (furosemide and thiazides), dimethylsulfoxide (DMSO), methotrexate, probenecid, propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing aspirin or cytotoxic chemotherapy drugs.
  • Willingness to forego concurrent use of supplements containing omega-3 fatty acids, , non-steroidal anti-inflammatory drugs or other FAP directed drug therapy.
  • Able to provide informed consent and follow protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Prior pelvic irradiation.
  • Patients receiving oral within 30 days of enrollment.
  • Treatment with other agents in the prior 4 weeks.
  • Use of other non-steroidal anti-inflammatory drugs (such as ibuprofen) exceeding 4 days per month, in the prior 6 weeks.
  • Regular use of aspirin in excess of 700 mg per week.
  • Treatment with other FAP directed drug therapy (including sulindac or celecoxib, fish oil) within 12 weeks of study enrollment.
  • to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; NSAID associated symptoms of gastritis.
  • Patients must not have cardiovascular disease risk factors as defined below:

    • Uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg
    • Unstable angina
    • History of documented myocardial infarction or cerebrovascular accident
    • Class III or IV heart failure
    • Known uncontrolled hyperlipidemia defined as LDL-C >= 190 mg/dL or triglycerides >= 500 mg/dL
  • Patients with significant hearing loss are not eligible for study participation defined as hearing loss that affects everyday life and/or for which a hearing aid is required.
  • Colon/rectum/pouch with high grade dysplasia or cancer on or a large polyp (>1 cm) not amenable to complete removal.
  • Duodenal cancer on biopsy.
  • Intra-abdominal desmoid disease, stage III or IV
  • Inability to provide .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Eflornithine plus Sulindac

    Eflornithine 750 mg and Sulindac 150 mg

    Drug: Eflornithine · Drug: Sulindac 150 MG

  • Active comparator
    Eflornithine plus Sulindac Placebo

    Eflornithine 750 mg and Placebo

    Drug: Eflornithine · Drug: Sulindac placebo

  • Active comparator
    Sulindac plus Eflornithine Placebo

    Sulindac 150 mg and Placebo

    Drug: Eflornithine Placebo · Drug: Sulindac 150 MG

Interventions

  • Eflornithine \[250 mg tablet, three tablets (750 mg) orally once a day\]

    Also known as: CPP-1X

  • DrugEflornithine Placebo

    Eflornithine placebo \[three tablets orally once a day\]

    Also known as: CPP-1X placebo

  • Sulindac \[one tablet orally once a day\]

    Also known as: Clinoril

  • DrugSulindac placebo

    Sulindac placebo \[one tablet orally once a day\]

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Any FAP-related Event.

    Progression of disease by evaluation of FAP-related events over the course of study treatment

    Time frame: Up to 48 months from the start of treatment

Secondary outcomes

  1. Improvement in Investigator Upper GI Assessment

    Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.

    Time frame: through month 12 assessment

  2. Improvement in Investigator Lower GI Assessment

    Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.

    Time frame: through month 12 assessment

07

Results

Posted Jun 8, 2021

Participant flow

Participant flow — Overall Study
MilestoneEflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine Placebo
Started565758
Completed414443
Not completed151315
Withdrew: Adverse event946
Withdrew: Withdrawal by subject025
Withdrew: Physician decision100
Withdrew: Lost to follow-up241
Withdrew: Protocol violation333

Outcome measures

PrimaryNumber of Subjects With Any FAP-related Event.

Progression of disease by evaluation of FAP-related events over the course of study treatment

Time frame:
Up to 48 months from the start of treatment
Reported as:
Count of participants · Participants
Number of Subjects With Any FAP-related Event.
ParticipantsEflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine Placebo
Number with FAP-related events182322
Number with Lower GI FAP-related events2109
Statistical analysis
  • Eflornithine Plus Sulindac vs Sulindac Plus Eflornithine Placebo · stratified Cox proportional (Score) · p = 0.1210 (The threshold for statistical significance is p=0.05) · Hazard ratio (hr): 0.71 · 95% CI 0.4 to 1.3Eflornithine plus sulindac is the numerator and sulindac plus eflornithine placebo is the denominator.
  • Eflornithine Plus Sulindac vs Eflornithine Plus Sulindac Placebo · stratified Cox proportional (Score) · p = 0.1076 (The threshold for statistical significance is p=0.05) · Hazard ratio (hr): 0.66 · 95% CI 0.4 to 1.2Eflornithine plus sulindac is the numerator and eflornithine plus sulindac placebo is the denominator.
  • Eflornithine Plus Sulindac vs Sulindac Plus Eflornithine Placebo · stratified Cox proportional (Score) · p = 0.0201 (Threshold for statistical significance was p=0.05) · Hazard ratio (hr): 0.20 · 95% CI 0.0 to 0.8Eflornithine and sulindac is the numerator and sulindac and eflornithine placebo is the denominator. Reduction in relative risk for FAP-related events with the combination.
  • Eflornithine Plus Sulindac vs Eflornithine Plus Sulindac Placebo · stratified Cox proportional (Score) · p = 0.0101 (Threshold of significance was p=0.05) · Hazard ratio (hr): 0.17 · 95% CI 0 to 0.7Eflornithine and sulindac is the numerator and eflornithine and sulindac placebo is the denominator.
SecondaryImprovement in Investigator Upper GI Assessment

Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.

Time frame:
through month 12 assessment
Reported as:
Count of participants · Participants
Improvement in Investigator Upper GI Assessment
ParticipantsEflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine Placebo
Improved111010
Not Improved454748
Statistical analysis
  • Eflornithine Plus Sulindac vs Sulindac Plus Eflornithine Placebo · Mantel Haenszel · p = 0.8127 (The threshold of significance was p=0.05)
  • Eflornithine Plus Sulindac vs Eflornithine Plus Sulindac Placebo · Mantel Haenszel · p = 0.8133 (The threshold for significance was p=0.05)
SecondaryImprovement in Investigator Lower GI Assessment

Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.

Time frame:
through month 12 assessment
Reported as:
Count of participants · Participants
Improvement in Investigator Lower GI Assessment
ParticipantsEflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine Placebo
Improved221622
Not Improved344136
Statistical analysis
  • Eflornithine Plus Sulindac vs Sulindac Plus Eflornithine Placebo · Mantel Haenszel · p = 0.999 (The threshold for significance was p=0.05)
  • Eflornithine Plus Sulindac vs Eflornithine Plus Sulindac Placebo · Mantel Haenszel · p = 0.2152 (The threshold for significance was p=0.05)

Adverse events

Collected over Up to 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eflornithine Plus Sulindac0/56 (0%)11/56 (19.6%)52/56 (92.9%)
Eflornithine Plus Sulindac Placebo0/56 (0%)14/56 (25%)49/56 (87.5%)
Sulindac Plus Eflornithine Placebo0/57 (0%)11/57 (19.3%)50/57 (87.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventEflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine Placebo
small intestinal obstructionGastrointestinal disorders2/561/562/57
abdominal painGastrointestinal disorders1/560/561/57
ileusGastrointestinal disorders1/561/560/57
constipationGastrointestinal disorders0/561/560/57
inguinal herniaGastrointestinal disorders1/560/560/57
pancreatitisGastrointestinal disorders0/561/560/57
pancreatitis acuteGastrointestinal disorders1/560/560/57
biliary colicHepatobiliary disorders0/561/560/57
alcohol poisoningInjury, poisoning and procedural complications0/561/560/57
post procedural hemorrhageInjury, poisoning and procedural complications0/561/560/57
Most frequent other events
Showing 10 of 55
Most frequent other events
EventEflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine Placebo
nauseaGastrointestinal disorders12/569/5612/57
headacheNervous system disorders8/565/5611/57
nasopharyngitisInfections and infestations6/5610/564/57
vomitingGastrointestinal disorders6/567/5610/57
diarrhoeaGastrointestinal disorders7/568/566/57
abdominal painGastrointestinal disorders8/564/568/57
fatigueGeneral disorders4/568/568/57
upper respiratory tract infectionInfections and infestations8/562/568/57
abdominal pain upperGastrointestinal disorders7/564/561/57
rectal haemorrhageGastrointestinal disorders7/564/567/57

Baseline characteristics

Age, Continuous
Age, Continuous(years)Eflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine PlaceboTotal
Mean37.8 ± 13.3539.7 ± 14.7638.1 ± 13.6638.5 ± 13.88
Sex: Female, Male
Sex: Female, Male(Participants)Eflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine PlaceboTotal
Female22292172
Male34283799
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine PlaceboTotal
Hispanic or Latino55313
Not Hispanic or Latino505054154
Unknown or Not Reported1214
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine PlaceboTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American61310
White485450152
More than one race0022
Unknown or Not Reported2226
Region of Enrollment
Region of Enrollment(participants)Eflornithine Plus SulindacEflornithine Plus Sulindac PlaceboSulindac Plus Eflornithine PlaceboTotal
Canada66416
Netherlands46515
Belgium1304
United States313042103
United Kingdom3328
Germany96419
Spain2316
08

Study locations

17 sites
  • University of California San Diego
    La Jolla, California 92093, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah- Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • UZ Leuven
    Leuven, 3000, Belgium
  • Zane Cohen Centre For Digestive Diseases
    Toronto, Ontario M5T 3L9, Canada
  • University Hospital Bonn
    Bonn, 53105, Germany
  • Academic Medical Centre
    Amsterdam, 1100 DE, Netherlands
  • Institut de Malalties Digestives
    Barcelona, Catalonia 08036, Spain
  • Institute of Genetic Medicine
    Newcastle Upon Tyne, Tyne And Wear NEI 3BZ, United Kingdom
  • Manchester Center for Genomic Medicine
    Manchester, M13 NWL, United Kingdom
09

References and documents

Publications

  • Burke CA, Dekker E, Samadder NJ, Stoffel E, Cohen A. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial. BMC Gastroenterol. 2016 Aug 2;16(1):87. doi: 10.1186/s12876-016-0494-4. PubMed 27480131 ↗
  • Burke CA, Dekker E, Lynch P, Samadder NJ, Balaguer F, Huneburg R, Burn J, Castells A, Gallinger S, Lim R, Stoffel EM, Gupta S, Henderson A, Kallenberg FG, Kanth P, Roos VH, Ginsberg GG, Sinicrope FA, Strassburg CP, Van Cutsem E, Church J, Lalloo F, Willingham FF, Wise PE, Grady WM, Ford M, Weiss JM, Gryfe R, Rustgi AK, Syngal S, Cohen A. Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. N Engl J Med. 2020 Sep 10;383(11):1028-1039. doi: 10.1056/NEJMoa1916063. PubMed 32905675 ↗
  • Balaguer F, Stoffel EM, Burke CA, Dekker E, Samadder NJ, Van Cutsem E, Lynch PM, Wise PE, Huneburg R, Lim RM, Boytim ML, Du W, Bruckheimer EM, Cohen A, Church J; FAP-310 Investigators. Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial. Dis Colon Rectum. 2022 Apr 1;65(4):536-545. doi: 10.1097/DCR.0000000000002095. PubMed 34261858 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Nov 2018 and a completion of Mar 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2021, 2 years 7 months after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2011
First posted
Dec 1, 2011
Start
Oct 2013
Primary completionActual
Nov 2018
CompletionActual
Mar 2019
Results delay requested
Jan 28, 2020
Results first posted
Jun 8, 2021
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01483144
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 1, 2011
Start date
Oct 2013
Primary completion
Nov 2018
Completion
Mar 2019
Results posted
Jun 8, 2021
Last update
Jun 8, 2021

Study contacts

Carol Burke, M.D.
principal investigator · The Cleveland Clinic
James Church, M.D.
principal investigator · The Cleveland Clinic
Gabriella Möslein, M.D.
principal investigator · Helios Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eflornithine · Sulindac

Start the discussion